Gossamer Bio (GOSS) Reiterated at Overweight by Cantor Fitzgerald: Phase 3 Readout in Feb Jan 22, 2026 07:45AM
Gossamer Bio's (GOSS) Seralitinib Data Likely Comes Out by Feb - Cantor Fitzgerald Nov 13, 2025 07:29AM
Cantor Fitzgerald Reiterates Overweight Rating on Gossamer Bio Inc. (GOSS) Sep 11, 2025 06:49AM
Cantor Fitzgerald Reiterates Overweight Rating on Gossamer Bio Inc. (GOSS) May 16, 2025 06:45AM
Gossamer Bio Announces Participation in Upcoming Investor Conferences Sep 10, 2020 07:07AM


Jul 14, 2020 06:27AM Gossamer Bio Inc. (GOSS) PT Raised to $33 at Cantor Fitzgerald; 'GB004 has best-in-class potential'
May 19, 2020 09:30AM Pre-Open Stock Movers 05/19: (ABUS) (DVAX) (AAP) Higher; (BLPH) (GMDA) (GOOS) Lower (more...)
May 18, 2020 05:44PM After-Hours Stock Movers 05/18: (ABUS) (DAC) (BIDU) Higher; (BLPH) (GMDA) (GOSS) Lower (more...)
Dec 17, 2019 06:34AM Gossamer Bio Inc. (GOSS) PT Lowered to $25 at Cantor Fitzgerald
Dec 6, 2019 06:20AM Cantor Fitzgerald Starts Gossamer Bio Inc. (GOSS) at Overweight